［1］ Cao X, Song L N, Yang J K. ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders［J］. Clin Sci (Lond), 2021, 135(3): 535－554.
［2］ Cao X, Shi T T, Zhang C H, et al. ACE2 pathway regulates thermogenesis and energy metabolism［J］. Elife, 2022, 11: e72266.
［3］ Prasad R, Adu A Y, Floyd J L, et al. Sustained ACE2 expression by probiotic improves integrity of intestinal lymphatics and retinopathy in type 1 diabetic model［J］. J Clin Med, 2023, 12(5): 1771.
［4］ Li R, Li F Y, Yuan L. ACE2 regulates glycolipid metabolism in multiple tissues［J］. Front Biosci: Landmark Ed, 2024, 29(1): 17.
［5］ Gheblawi M, Wang K M, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2［J］. Circ Res, 2020, 126(10): 1456－1474.
［6］ Camargo S M R, Vuille-Dit-Bille R N, Meier C F, et al. ACE2 and gut amino acid transport［J］. Clin Sci (Lond), 2020, 134(21): 2823－2833.
［7］ Yu W, Ou X H, Liu X F, et al. ACE2 contributes to the maintenance of mouse epithelial barrier function［J］. Biochem Biophys Res Commun, 2020, 533(4): 1276－1282.
［8］ Prasad R, Floyd J L, Dupont M, et al. Maintenance of enteral ACE2 prevents diabetic retinopathy in type 1 diabetes［J］. Circ Res, 2023, 132(1): e1-e21.
［9］ Zhang C H, Cao X Y, Wang H H, et al. The ACE2 activator diminazene aceturate ameliorates colitis by repairing the gut-vascular barrier in mice［J］. Microvasc Res, 2023, 148: 104544.
［10］ Sztal T E, Stainier D Y R. Transcriptional adaptation: a mechanism underlying genetic robustness［J］. Development, 2020, 147(15): dev186452.
［11］ Verma A, Xu K, Du T, et al. Expression of human ACE2 in Lactobacillus and beneficial effects in diabetic retinopathy in mice［J］. Mol Ther Methods Clin Dev, 2019, 14: 161－170.
［12］ Li Z L, Peng M X, Chen P, et al. Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry［J］. Cell Metab, 2022, 34(3): 424－440.e7.
［13］ Pupo A, Fernández A, Low S H, et al. AAV vectors: the Rubiks cube of human gene therapy［J］. Mol Ther, 2022, 30(12): 3515－3541.
［14］ 陈平, 张利娟. 腺相关病毒载体的研究进展［J］. 中国生物制品学杂志, 2022, 35(4): 500－507.
［15］ Polyak S, Mah C, Porvasnik S, et al. Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5［J］. Dig Dis Sci, 2008, 53(5): 1261－1270.
［16］ Buckinx R, Van Remoortel S, Gijsbers R, et al. Proof-of-concept: neonatal intravenous injection of adeno-associated virus vectors results in successful transduction of myenteric and submucosal neurons in the mouse small and large intestine［J］. Neurogastroenterol Motil, 2016, 28(2): 299－305.
［17］ During M J, Xu R, Young D, et al. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector［J］. Nat Med, 1998, 4(10): 1131－1135.
［18］ Ma L T, Lian J X, Bai Y, et al. Adeno-associated virus vector intraperitoneal injection induces colonic mucosa and submucosa transduction and alters the diversity and composition of the Faecal microbiota in rats［J］. Front Cell Infect Microbiol, 2022, 12: 1028380.
［19］ Chen Q, Gao F, Gao Y Y, et al. Intestinal ACE2 regulates glucose metabolism in diet-induced obese mice through a novel gut-islet axis mediated by tryptophan［J］. Obesity (Silver Spring), 2023, 31(5): 1311－1325.
［20］ Polyak S, Mach A, Porvasnik S, et al. Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis［J］. Am J Physiol Gastrointest Liver Physiol, 2012, 302(3): G296-G308.
［21］ Oudit G Y, Wang K M, Viveiros A, et al. Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic［J］. Cell, 2023, 186(5): 906－922.
［22］ Oliveira L P, Guimarães V H D, Oliveira J R, et al. Genetic deletion of the angiotensin-(1－7) receptor Mas leads to alterations in gut villi length modulating TLR4/PI3K/AKT and produces microbiome dysbiosis［J］. Neuropeptides, 2020, 82: 102056.
［23］ Wang D, Tai P W L, Gao G P. Adeno-associated virus vector as a platform for gene therapy delivery［J］. Nat Rev Drug Discov, 2019, 18(5): 358－378.
［24］ Blanc F, Mondain M, Bemelmans A P, et al. rAAV-mediated cochlear gene therapy: prospects and challenges for clinical application［J］. J Clin Med, 2020, 9(2): 589.
［25］ Porvasnik S L, Mah C, Polyak S. Targeting murine small bowel and colon through selective superior mesenteric artery injection［J］. Microsurgery, 2010, 30(6): 487－493.
［26］ Drouyer M, Merjane J, Nazareth D, et al. Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in mice［J］. Mol Ther, 2024, 32(3): 818－836.
［27］ Setayesh T, Hu Y, Vaziri F, et al. Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma［J］. Acta Pharm Sin B, 2024, 14(1): 292－303.
［28］ Chu C N, Wang X Y, Yang C, et al. Neutrophil extracellular traps drive intestinal microvascular endothelial ferroptosis by impairing fundc1-dependent mitophagy［J］. Redox Biol, 2023, 67: 102906.
|
